Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Retained Earnings (2016 - 2025)

Cumberland Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at -$26.8 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 11.83% year-over-year to -$26.8 million; the TTM value through Dec 2025 reached -$26.8 million, down 11.83%, while the annual FY2025 figure was -$26.8 million, 11.83% down from the prior year.
  • Retained Earnings for Q4 2025 was -$26.8 million at Cumberland Pharmaceuticals, down from -$25.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$735625.0 in Q2 2021 and bottomed at -$26.8 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$11.2 million (2023), against an average of -$13.8 million.
  • The largest YoY upside for Retained Earnings was 3.9% in 2021 against a maximum downside of 1385.67% in 2021.
  • A 5-year view of Retained Earnings shows it stood at -$5.6 million in 2021, then tumbled by 98.79% to -$11.2 million in 2022, then increased by 0.13% to -$11.2 million in 2023, then plummeted by 114.12% to -$24.0 million in 2024, then dropped by 11.83% to -$26.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Retained Earnings are -$26.8 million (Q4 2025), -$25.4 million (Q3 2025), and -$23.5 million (Q2 2025).